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Abstract 
Objective: The mortality associated with sepsis remains unacceptably high, despite modern high-quality intensive 
care. Based on the results from previous studies, anaemia and its management in patients with sepsis appear to 
impact outcomes; however, the transfusion policy is still being debated, and the ideal approach may be extremely 
specific to the individual. This study aimed to investigate the long-term impact of anaemia requiring red blood cell 
(RBC) transfusion on mortality and disease severity in patients with sepsis. We studied a general surgical intensive 
care unit (ICU) population, excluding cardiac surgery patients. 435 patients were enrolled in this observational study 
between 2012 and 2016.
Results: Patients who received RBC transfusion between 28 days before and 28 days after the development of sepsis 
(n = 302) exhibited a significantly higher 90-day mortality rate (34.1% vs 19.6%; P = 0.004, Kaplan–Meier analysis). This 
association remained significant after adjusting for confounders in the multivariate Cox regression analysis (hazard 
ratio 1.68; 95% confidence interval 1.03–2.73; P = 0.035). Patients who received transfusions also showed significantly 
higher morbidity scores, such as SOFA scores, and ICU lengths of stay compared to patients without transfusions 
(n = 133). Our results indicate that anaemia and RBC transfusion are associated with unfavourable outcomes in 
patients with sepsis.
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Introduction
Despite the significant improvements in critical care 
medicine and intensive research in the field, sepsis and 
related organ dysfunction remain major causes of mor-
tality, even in the developed world [1]. The pathophysi-
ology of organ failure in patients with life-threatening 
infections is diverse, including direct cytotoxicity of 
bacterial toxins, collateral damage through inflamma-
tion, and tissue ischemia [2–4]. Since the dysregulation 
of the microcirculation is common in patients with sepsis 
[4–7], inadequate perfusion of organs may occur, even if 
cardiac output and systemic blood pressure are formally 
in the normal range. Given the reduced density of func-
tioning capillaries in patients with sepsis, theoretical 
considerations suggest that this patient group might be 
more sensitive to anaemia, which is indeed very com-
mon in septic patients. Anaemia is related to haemolysis, 
impaired blood clotting with a bleeding tendency and 
decreased erythrocyte growth [8, 9]. Under these cir-
cumstances, the intended benefit of RBC transfusion is 
to increase oxygen delivery to starving organs; however, 
the correction of anaemia in this patient group is by far 
a more complex question in the clinical setting than at 
the theoretical level [10–14]. Although life-threatening 
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transfusion-related adverse reactions are relatively rare 
from the classical perspective [15], the administration of 
blood products represents an allogenic transplantation, 
which raises several questions. Regarding erythrocytes, 
the most problematic aspects include transfusion-related 
immunomodulation [16, 17], impaired rheological prop-
erties and reduced oxygen release from stored RBCs [18–
20]. Additionally, microparticles originating from stored 
RBCs exert detrimental effects on homeostasis, including 
the promotion of coagulation and immunomodulation 
[21].
Based on two studies revealing the lack of additional 
benefits of a liberal transfusion regimen from a statistical 
perspective, recent guidelines recommend a transfusion 
threshold of 7  g/dL for septic patients without further 
risk factors, such as myocardial ischemia, severe hypox-
emia or acute blood loss [13, 22, 23]. However, a differ-
ent study concluded that septic patients who received 
RBC transfusions exhibited reduced 7-day, 28-day and 
in-hospital mortality after adjustment in the multivari-
ate analysis [24]. These data indicate the heterogeneity of 
patient groups with sepsis. Indeed, a recent large meta-
analysis confirmed that “the data on RBC transfusions in 
patients with sepsis are sparse, and the high heterogeneity 
between studies prevents from drawing any definitive con-
clusions” [25]. We focused on a general surgical ICU pop-
ulation with sepsis, excluding cardiac surgery patients 
due to their particularly high bleeding risk, to investigate 
the possible associations between anaemia, blood trans-
fusions and outcomes in a homogeneous patient group. 
Unlike most previous studies, we chose a long (90-day) 
observation period for mortality as the primary outcome. 
Because of the immunomodulatory effects of stored allo-
genic erythrocytes, RBC transfusions as early as 28 days 
before the beginning of sepsis were considered. The 
observation period for transfusion was then continued 
for an additional 28 days after enrolment.
Main text
Materials and methods
Study population
Surgical patients with sepsis were recruited through the 
GENOSEP database of the Department of Anesthesiol-
ogy at the University Medical Center, Goettingen, Ger-
many. This database comprises a prospectively collected 
cohort of ICU patients with sepsis. All patients treated 
at the surgical ICUs of the University Medical Center 
Goettingen between March 2012 and March 2016 were 
screened for sepsis on a daily basis as described previ-
ously [26–28]. Sepsis was defined according to the 2012 
standards as a microbiologically or clinically obvious 
infection with the presence of two or more systemic 
inflammatory response syndrome (SIRS) criteria, because 
the new ‘sepsis 3’ definition was not available at the 
beginning of the study [29]. The exclusion criteria were 
an age less than 18 years, pregnancy, therapy with immu-
nosuppressive drugs or chemotherapy, human immuno-
deficiency virus (HIV) infection, chronic heart failure 
classified as New York Heart Association (NYHA) stage 
IV, or acute myocardial infarction. Moribund patients 
were also excluded. No patients enrolled in this study 
were lost to follow-up. Cardiac surgery patients were not 
enrolled in this study because of their disproportionally 
high risk of bleeding.
Collection of data
On day 1 (beginning of sepsis and enrolment in the 
study), the following data were collected: age, gen-
der, pre-existing medical conditions and medications, 
focus of infection, and SOFA and Acute Physiology and 
Chronic Health Evaluation (APACHE II) scores. The 
patients were then followed for 28 days. Over the course 
of the ICU stay, the following data were collected: vital 
parameters, routine blood tests, including a blood gas 
analysis, SOFA score, organ support (renal replacement 
therapy, mechanical ventilation, and vasopressors), anti-
biotics used and culture results. Days without organ sup-
port were the number of days in the 28-day observation 
period a patient did not require organ support therapy. 
We obtained data on the transfusion of erythrocytes in 
the timeframe of 28  days before and 28  days after the 
beginning of sepsis. On day 90, the status of our enrolled 
patients was evaluated.
Data analysis
We used Statistica Software (Version 13, StatSoft, Tulsa, 
Oklahoma, USA) to analyse the data. The significance 
of the categorical variables was calculated using Pear-
son’s Chi Square test. Continuous variables were com-
pared using the Mann–Whitney U test. The mortality 
risk analysis was performed by comparing time-to-event 
data using the log-rank test. We performed a multivariate 
Cox regression analysis to exclude the effects of poten-
tial confounders and covariates that varied at baseline 
(e.g., comorbidities) on survival. P values ≤ 0.05 were 
considered significant. In tables, continuous variables 
are presented as means ± standard deviations and cat-
egorical variables are presented as absolute numbers or 
percentages.
Results
Baseline characteristics at the time of enrolment
435 Caucasian patients with sepsis who were admitted 
to the surgical ICUs of the University Medical Center 
Goettingen were enrolled in this study. Patients in the 
transfusion group (n = 302) exhibited significantly higher 
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baseline SOFA scores (9.5 ± 3.8 vs. 7.5 ± 3.0; P < 0.001), 
APACHE II scores (21.6 ± 6.6 vs. 19.0 ± 6.1; P < 0.001) 
and an increased prevalence of septic shock on day 1 
(69% vs. 51%; P < 0.001) compared with patients in the 
non-transfusion group (n = 133). Patients who received 
an RBC transfusion required significantly more vaso-
pressors (69% vs. 51%; P < 0.001) and renal replacement 
therapy (9% vs. 2%; P = 0.004) at baseline. The transfusion 
group more frequently had a previous medical history of 
malignant tumours than the transfusion-free group (23% 
vs. 12%; P = 0.007), whereas a previous history of stroke 
was rarer in these patients (4% vs. 10%; P = 0.027). No 
differences in age, gender and comorbidities other than 
those mentioned above were identified. Although a pul-
monary focus followed by an abdominal focus was the 
most frequent site of infection, patients who received 
an RBC transfusion experienced a significantly greater 
incidence of an abdominal focus as site of infection than 
patients in the transfusion-free group (32% vs. 16%; 
P = 0.046). All data on baseline characteristics are shown 
in Table 1.
Mortality analysis
Patients who received RBC transfusion showed a signifi-
cantly higher 90-day mortality risk than patients without 
an RBC transfusion, in the Kaplan–Meier survival analy-
sis (34.1% vs. 19.6%; P = 0.004; Fig. 1). A higher mortality 
risk among patients in the RBC group was also observed 
at the 28-day time point, although this difference was not 
significant (20.2% vs. 13.5%; P = 0.1; Table 2).
Multivariate analysis
A multivariate Cox regression analysis was performed 
to adjust for possible effects of different baseline 
Table 1 Baseline characteristics of surgical patients with sepsis
Italic indicates significance of P values (P < 0.05)
Parameter All surgical patients (n = 435) Patients who received 
an RBC transfusion 
(n = 302)
Patients without an RBC 
transfusion (n = 133)
P value
Age (years) 62 ± 15 63 ± 15 61 ± 15 0.25
Gender (male %) 64 63 65 0.66
BMI (kg/m2) 27 ± 6 27 ± 5 28 ± 7 0.93
Septic shock (day 1) [%] 63 69 51 0.0004
SOFA score (day 1) 8.9 ± 3.7 9.5 ± 3.8 7.5 ± 3.0 < 0.001
APACHE II score (day 1) 20.8 ± 6.5 (n = 430) 21.6 ± 6.6 (n = 300) 19.0 ± 6.1 (n = 130) 0.0002
Comorbidities (%)
 Arterial hypertension 52 50 56 0.22
 Previous myocardial infarction 5 6 2 0.12
 COPD 12 14 8 0.12
 Kidney disease 9 10 6 0.22
 Diabetes mellitus (insulin-dependent) 9 10 9 0.85
 Diabetes mellitus (not insulin-dependent) 8 7 10 0.31
 Chronic liver disease 6 7 4 0.24
 Malignant tumour 20 23 12 0.0072
 Stroke 6 4 10 0.0266
Site of infection (%)
 Pulmonary 56 52 66 0.14
 Abdominal 28 32 16 0.0457
 Bones or soft tissues 4 5 2 0.45
 Surgical wounds 2 2 2 0.54
 Urogenital 2 2 3 0.73
 Primary bacteraemia 4 5 2 0.58
 Other 4 2 7 0.0130
Organ support (day 1) [%]
 Mechanical ventilation 85 86 83 0.53
 Vasopressors 63 69 51 0.0004
 Renal replacement therapy 7 9 2 0.0042
Medication with statins [%] 20 22 16 0.13
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characteristics and potential confounders on 90-day 
mortality. It included RBC transfusion, potential con-
founders (age, gender and SOFA and APACHE II scores), 
and covariates that varied at baseline (septic shock, a 
medical history of tumours or stroke, abdominal foci 
and other foci as sites of infection, and vasopressors and 
renal replacement therapy on day 1). The transfusion of 
RBCs was independently associated with a higher 90-day 
mortality (hazard ratio (HR) 1.68; 95% confidence inter-
val (CI) 1.03–2.73; P = 0.035). Further independent risk 
factors included an age greater than 65  years (HR 1.59; 
95% CI 1.08–2.36; P = 0.020) and a higher APACHE II 
score on day 1 (HR 1.04; 95% CI 1.00–1.08; P = 0.043). 
Patients with an abdominal focus exhibited a significantly 
better outcome (HR 0.23; 95% CI 0.06–0.85; P = 0.007). 
Data are presented in Additional file 1: Table S1.
Disease severity
The transfusion group showed a higher average SOFA 
score during their ICU stay than the group without 
an RBC transfusion (7.1 ± 3.4 vs. 5.2 ± 2.1; P < 0.001). 
Regarding the SOFA score, patients transfused with 
RBCs scored higher on the SOFA-Respiratory system, 
SOFA-Kidney, SOFA-Cardiovascular system, SOFA-
Liver and SOFA-Coagulation subscales. The transfusion 
group also showed a longer average ICU length of stay 
(20 ± 15 vs. 12 ± 7 days; P < 0.001) than the non-transfu-
sion group.
The microbiological spectrum of pathogens isolated 
from cultures of the two patient groups were similar with 
respect to Gram-positive and Gram-negative pathogens. 
However, the transfusion group exhibited a significantly 
higher number of positive fungal cultures (62% vs. 35%; 
P < 0.001). Disease severity data are illustrated in Table 2.
Discussion
In this observational study, we investigated the relation-
ship between anaemia requiring an RBC transfusion 
Fig. 1 Kaplan–Meier 90-day survival analysis
Table 2 Disease severity of surgical patients with sepsis
Italic indicates significance of P values (P < 0.05)
Parameter All surgical patients 
(n = 435)
Patients who received an RBC 
transfusion (n = 302)
Patients without an RBC 
transfusion (n = 133)
P value
SOFA score 6.5 ± 3.2 7.1 ± 3.4 5.2 ± 2.1 < 0.001
SOFA-respiratory system 1.8 ± 0.8 1.9- ± 0.8 1.6 ± 0.7 0.0005
SOFA-kidneys 0.6 ± 1.0 0.8 ± 1.1 0.2 ± 0.6 < 0.001
SOFA-cardiovascular system 1.4 ± 0.9 1.6 ± 0.9 1.1 ± 0.9 < 0.001
SOFA-liver 0.3 ± 0.7 0.4 ± 0.7 0.1 ± 0.4 < 0.001
SOFA-coagulation 0.3 ± 0.5 0.3 ± 0.6 0.1 ± 0.2 < 0.001
SOFA-nervous system 2.0 ± 1.1 2.0 ± 1.1 2.0 ± 1.1 0.86
28-day mortality (%) 18 20.2 13.5 0.10
ICU length of stay (from the beginning of sepsis 
to discharge)
17 ± 13 20 ± 15 12 ± 7 < 0.001
Days without organ support
 Days without mechanical ventilation 5 ± 5 5 ± 6 4 ± 4 0.59
 Days without vasopressors 13 ± 8 13 ± 8 12 ± 7 0.19
 Days without renal replacement therapy 24 ± 10 14 ± 10 15 ± 8 0.70
Type of infection (%)
 Gram-positive bacteria 83 84 80 0.31
 Gram-negative bacteria 69 69 71 0.66
 Fungal infection 54 62 35 < 0.001
 Viral infection 11 12 10 0.58
Page 5 of 7Kristof et al. BMC Res Notes          (2018) 11:879 
and 90-day mortality in surgical ICU patients with sep-
sis. The main finding of the study was that the transfu-
sion of stored allogenic RBCs in a timeframe of 28 days 
before and after the beginning of sepsis was associated 
with a significantly higher 90-day mortality risk. This 
association remained significant after adjustment for 
confounders.
A causal relationship underlying the higher mortal-
ity rate observed in the transfusion group cannot be 
undisputedly determined from these data. It might be 
explained by anaemia itself or alternatively by numer-
ous mechanisms by which stored allogenic erythrocytes 
detrimentally effect homeostasis. Some of these mecha-
nisms, such as impaired rheological properties, reduced 
oxygen release or the procoagulant effects of RBC-
derived microparticles [18–21, 30], develop imme-
diately. Other unfavourable phenomena, particularly 
transfusion-related immunomodulation (TRIM), evolve 
over a prolonged period [31]. The mechanisms involved 
in TRIM are not completely understood, but modula-
tion of cellular immunity is suggested to play a key role 
[32]. The observation that transfusion decreases the 
probability of rejection of cardiac and renal allografts 
[33–35] also supports the hypothesis that stored blood 
cells exert a lasting modulatory effect on immunity. The 
increase in the mortality gap between the transfusion 
and non-transfusion groups during the observation 
period noted in the present study might support the 
theory of a probable dominance of some immunologi-
cal mechanisms responsible for poorer outcomes. The 
presence of complex immunomodulation associated 
with RBC transfusion in our patients is also supported 
by the significantly higher prevalence of positive fungal 
cultures in the transfusion group.
Septic patients requiring an RBC transfusion showed 
a more severe presentation of the disease. Upon enrol-
ment, SOFA and APACHE II scores were significantly 
higher in the transfusion group, and these patients 
required more vasopressors and renal replacement 
therapy on day 1. During the observation period, aver-
age SOFA scores remained significantly higher in 
patients who received allogenic RBCs. All SOFA sub-
scores, with the exception of the SOFA-Central nerv-
ous system score, were higher in this group.
We also investigated the association between RBC 
transfusions and pre-existing medical conditions. 
Patients who received an allogenic blood transfu-
sion were significantly more likely to have some type 
of malignant tumour in their medical history than 
patients in the non-transfusion group. This finding is 
consistent with the observation that anaemia is indeed 
very common in patients with malignant tumours [36].
Conclusions
Apart from the mentioned limitations, our findings imply 
that anaemia requiring the transfusion of stored RBCs 
in patients with sepsis is associated with higher 90-day 
mortality rates and disease severity. Further research is 
needed to determine causal relations.
Limitations
This observational study has some limitations that need 
to be highlighted. In our study, we focused on the gen-
eral surgical ICU population with sepsis; therefore, our 
results may not be completely applicable to other ICU 
cohorts. Furthermore, the haemoglobin concentration 
before the transfusion was not recorded; thus, we were 
not able to determine whether patients were transfused 
according to a restrictive or liberal strategy. However, 
according to the standard operating procedures of our 
ICUs, patients rarely receive an RBC transfusion if they 
have a haemoglobin concentration greater than 8  g/dL. 
Although we observed significant associations between 
RBC transfusion and sepsis-related mortality and dis-
ease severity, our findings do not reveal the causal and 
biological relations of these observed associations. We 
postulated that the RBC transfusion exerted a detrimen-
tal effect on sepsis outcomes and severity, and patients 
with a more severe case of sepsis and concomitant anae-
mia might receive RBC transfusions more frequently. The 
biological mechanisms underlying our findings must be 
investigated in further studies.
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